Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 29 Sept, 15:52 UTC

The deal, which hands Novo a challenger to Lilly’s market-leading Zepbound, comes as the Danish drugmaker looks to calm investor fears about its future.

science

Sources

• T2Novo to pay Hengrui up to $2.6B for a once-weekly obesity pillBioPharma Dive / Healthcare Dive / MedTech Dive29 Sept, 15:52